Global Osteomyelitis Market Size, Share, Forecast Report, 2020-2027

The global osteomyelitis market is expected to register an approximate CAGR of 6.1% during the forecast period. In the recent years, the prevalence of osteomyelitis has increased, providing favorable backgrounds for the market to grow. According to NCBI in 2016 the total annual occurrence rate of osteomyelitis was 13 per 100,000 (acute osteomyelitis eight and subacute osteomyelitis five per 100,000) globally. Due to the increasing prevalence of osteomyelitis, the market will witness huge demand for treatments, thus, driving the global osteomyelitis market.

Moreover, in 2016, the International Journal of Environmental Research and Public Health stated that the estimated occurrence rate of acute osteomyelitis is about eight cases per 100,000 children/year. According to the U.S. Census Bureau age projection sheet of 2017–2050, the child population is estimated to increase from 73.8 million in 2017 to 79.9 million by 2050. Moreover, according to the World Journal of Diabetes in 2017, diabetic patients are at a higher risk for osteomyelitis. In the recent, years, the prevalence of the osteomyelitis has increased. As per the American Diabetes Association in 2015, ~30.3 million Americans accounting for 9.4% of the population within the region had diabetes. The prevalence of diabetes is estimated to drive the market by increasing the susceptible population.

However, factors such as the limited availability of treatments, risks associated with surgeries, and low healthcare expenditure in the middle and low-income countries are estimated to hinder the market growth during the forecast period.

Segmentation

The global osteomyelitis market is segmented on the basis of type, diagnosis, treatment, and end-user.

The osteomyelitis market, by type, is further segmented by duration, pathogenesis, and others. The duration segment is sub-segmented into acute and chronic. The pathogenesis segment is sub-segmented into trauma, contiguous spread, and others. By diagnosis, the market is categorized into physical examination, blood tests, imaging tests, bone biopsy, and others. The blood tests segment is sub-segmented into Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP). The imaging segment is sub-segmented into X-rays, Computerized Tomography (CT) scan, and Magnetic Resonance Imaging (MRI). By treatment, the market is segmented into antibiotics and surgery. The antibiotics segment is sub-segmented into ceftriaxone, nafcillin, ceftazidime, and others. On the basis of end-user, the market is segmented into hospitals and clinics, research organizations, diagnostic diseases, and others.
Key players

Some of the key players for the global osteomyelitis market are Allergan Plc (Republic of Ireland) CrystalGenomics Inc (South Korea), Debiopharm International SA (Lausanne), Motif Bio Plc (London), Nabriva Therapeutics AG (Dublin), Vyome Biosciences Pvt Ltd (India), F. Hoffmann-La Roche AG (Switzerland), Koninklijke Philips N.V. (Netherlands), General Healthcare (U.S.), Siemens AG (Germany), Toshiba Corporation (Japan), Shimadzu Corporation (Japan), Samsung Electronics Co., Ltd. (South Korea), Neusoft Medical Systems Co., Ltd. (China), Medtronic plc (Ireland), Shenzhen Anke High-tech Co., Ltd. (Hong Kong), and others.

Global Osteomyelitis Market, by Diagnosis and Treatment

• Diagnosis
• Physical Examination
• Blood Tests
• Complete Blood Count (CBC)
• Erythrocyte Sedimentation Rate (ESR)
• C-Reactive Protein (CRP)
• Imaging Tests
• X-rays
• Computerized Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI)
• Others
• Bone Biopsy
• Treatment
• Antibiotics
• Ceftriaxone
• Nafcillin
• Ceftazidime
• Others
• Surgery

Global Osteomyelitis Market, by Pathogenesis

• Trauma
• Contiguous Spread
• Others

Global Osteomyelitis Market, by End-User

• Hospital and Clinics
• Research Organization
• Diagnostic Diseases
• Diagnostic Centers

Global Osteomyelitis Market, by Region

• The Americas
• Europe
• Asia Pacific
• The Middle East & Africa

Global Osteomyelitis Market, by Key Players

• Allergan Plc
• CrystalGenomics Inc
• Debiopharm International SA
• Motif Bio Plc
• Nabriva Therapeutics AG
• Hoffmann-La Roche AG
• Koninklijke Philips N.V.
• General Healthcare
• Siemens AG
• Toshiba Corporation
• Shimadzu Corporation
• Samsung Electronics Co., Ltd.
• Neusoft Medical Systems Co., Ltd.
• Medtronic plc
• Shenzhen Anke High-tech Co., Ltd.